GRAFT VERSUS HOST DISEASE

This early-stage study is testing whether adding one or two drugs to standard transplant care can better prevent two serious complications: graft-versus-host disease (where donor cells attack the patient's body) and cytokine release syndrome (a severe immune reaction). The trial …

This study is testing whether adding a drug called belumosudil to standard treatments can better prevent graft-versus-host disease (GVHD) in blood cancer patients who receive stem cell transplants. Researchers want to see if this approach helps patients live longer without GVHD o…

This study is testing whether adding an experimental drug called BPC2001 to standard care can better prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. The trial will enroll 50 adults with blood cancers who are receiving a transpl…

This study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …

This study is testing a new drug called Rovadicitinib for people with moderate-to-severe chronic graft-versus-host disease (cGVHD) who have already tried at least two other treatments. It aims to see if Rovadicitinib is better than other standard treatments at reducing symptoms a…

This early-stage trial is testing whether injecting a patient's own bone marrow cells into their salivary glands is safe and might help improve severe dry mouth. The study focuses on people whose dry mouth is caused by autoimmune conditions like Sjogren's disease or as a side eff…

This study is testing a new way to prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant for blood cancer. Researchers want to see if a short, intense course of two drugs (cyclophosphamide …

This study aims to find out if a lower dose of a key drug (cyclophosphamide) given after a stem cell transplant works as well as the standard dose to prevent graft-versus-host disease (GVHD). It will involve 316 patients receiving transplants from donors who are not a perfect mat…

This early-stage study is testing whether adding two pregnancy-related hormones (uhCG/EGF) to a standard drug (cyclophosphamide) can safely prevent graft-versus-host disease (GVHD) after a stem cell transplant from a mismatched donor. The trial will enroll 18 adults with blood ca…

This study is testing whether a virtual group support program can help people who have had a bone marrow transplant and are now living with a serious complication called chronic graft-versus-host disease. About 350 adults with moderate to severe symptoms will be randomly assigned…

This study is testing whether a special red light therapy can safely reduce painful mouth sores caused by chronic Graft-Versus-Host Disease (GVHD). It will involve 44 patients who have had a stem cell transplant and still have mouth sores despite previous treatments. Participants…

This study aims to develop better methods for preparing donor blood cells for bone marrow transplants. Researchers are working with healthy volunteers to collect blood cells and test ways to remove the white blood cells that can cause dangerous immune reactions in transplant pati…

This study aims to understand if there's a link between how a person's gut bacteria break down certain dietary carbohydrates (called FODMAPs) and their risk of developing graft-versus-host disease (GVHD) after a bone marrow transplant. Researchers will recruit 100 patients who ha…

This study is testing a special type of CT scan, called Parametric Response Mapping (PRM), to see if it can predict which patients will develop serious lung disease after a stem cell transplant. It will follow 375 children and adults who have either just been diagnosed with a tra…

This study aims to better understand mouth problems that can develop after a stem cell transplant from a donor, a condition called chronic graft-versus-host disease (cGVHD). Researchers will follow 500 adults—including both recent transplant patients and healthy volunteers—for up…